AAREYDRUGS vs NGLFINE: Stock Comparison

Aarey Drugs & Pharmaceuticals Limited vs NGL Fine-Chem Limited

Live data: 29 April 2026, 4:01 PM IST • Source: NSE and company filings

NGL Fine-Chem Limited is the larger company by market capitalisation. NGL Fine-Chem Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Aarey Drugs & Pharmaceuticals Limited and NGL Fine-Chem Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AAREYDRUGS is more favourable on 1 of 13 scored metrics and NGLFINE on 11These counts are context-free and are not an overall rating.

Key Differences

Market Cap
NGLFINE is the larger company
₹2,015 Cr vs ₹221 Cr
P/E Ratio
NGLFINE has a lower P/E
41.23x vs 55.36x
P/B Ratio
AAREYDRUGS has a lower P/B
1.46x vs 6.03x
EPS
NGLFINE has higher earnings per share
₹78.04 vs ₹1.47
Dividend Yield
NGLFINE has a higher dividend yield
0.05% vs 0%
Revenue Growth (TTM YoY)
NGLFINE has faster revenue growth
57.2% vs 19.8%
EPS Growth (TTM YoY)
NGLFINE has faster EPS growth
1,539.8% vs -41.05%
Qtr Sales Growth
NGLFINE has stronger quarterly sales growth
57.1% vs 0%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAAREYDRUGSNGLFINE
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAAREYDRUGSNGLFINE
Live Price₹90.51₹3,260
Day Change-4.92%0.7%
Volume2.2 L5,953
52-Week High₹96₹3,329
52-Week Low₹50.31₹1,175.5
Distance from 52W High-5.72%-2.07%

Valuation

MetricAAREYDRUGSNGLFINE
Market Cap₹221 Cr₹2,015 Cr
P/E Ratio55.36x41.23x
P/B Ratio1.46x6.03x
EPS₹1.47₹78.04
Book Value₹48.67₹532.95
Dividend Yield0%0.05%

Growth

MetricAAREYDRUGSNGLFINE
Revenue Growth (TTM YoY)19.8%57.2%
EPS Growth (TTM YoY)-41.05%1,539.8%
Qtr Sales Growth0%57.1%
Qtr Profit Growth0%2,398%

Profitability & Leverage

MetricAAREYDRUGSNGLFINE
ROE2.64%15.7%
ROCE6%17%
Net Margin0.84%9.59%
Operating Margin2.21%14.5%
Debt to Equity0.33x0.33x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricAAREYDRUGSNGLFINE
Promoter Holding37.71% 1.35 pp72.74%
FII Holding4.18% 0.32 pp0.03% 0.03 pp
DII Holding1.62% 1.62 pp0%
Public Holding56.49% 0.6 pp27.24% 0.02 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Aarey Drugs & Pharmaceuticals Limited and NGL Fine-Chem Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.